So I like the rate of recovery that we’re seeing in our base business. Yeah, so I guess we’re trying to triangulate here as much as we can, but we’re not going to put out a specific number. The next Abbott Laboratories dividend will go ex in 10 days for 45c and … We’re in a unique position, we’re not coming out of a hole, we’re going to be delivering what I would say, very high, strong double digit top and bottom line. Based on our performance and momentum through the first nine months, along with our expectations for the remainder of the year, we increased our earnings per share guidance to at least $3.55 for the full year. And I think it’s — it definitely sticks out a little bit in terms of our growth rate. And then I think that TriClip and Tendyne are multibillion-dollar opportunities here for us that are as I described, very, very early in the innings. The readings every minute, which is unique to Libre, allows us to get a better alarm performance. So I think we’re very well positioned to go from what is a very strong year for us in 2020, to an even stronger year in 2021. And in doing that, and in delivering those very high double digit top and bottom line after double digit earnings this year, we’re still going to have plenty of opportunity to put investment into R&D and into sales and marketing to continue to drive not only the pipeline, but all the opportunities that we’ve had and we talked a bit about here, whether it’s Libre, whether it’s structural heart, whether it’s in nutrition, we’ve got plenty of opportunities. Box 43078 abbott facts. So I think we had a nice sequential Q2 to Q3 kind of growth rate. Dividend Definition. Dividend Summary. But I think most of that is because there — a lot of them are going to be coming out of a hole [Phonetic], right, they’re going to have a certain amount of easy cons, especially if you look at like Q2 and Q3 this year. About bringing — about timing of Libre 3 in the US here, Robbie, I’m going to — I’m not going to provide details to you on that timing here. So we’ve actually built a team that’s separated from the diabetes group that’s just focused on developing this opportunity. Today we reported organic sales growth of 10.5%, and ongoing earnings per share of $0.98, which reflects high teens growth versus the prior year. So if the COVID assay itself, when will it ramp down two years, three years, okay, it’ll eventually ramp down to more of like a flue state kind of business. Your line is open. So in our numbers here, I think we’ve kind of excluded them. And our pipeline continues to be highly productive, resulting in several new product launches and approvals this past quarter, including US FDA emergency use authorization for our BinaxNOW, rapid antigen test, which can detect COVID-19 infection in just 15 minutes with no instrument required. You guys are really in an enviable position here. If you look at the businesses that were most hit by COVID, devices, and core lab, so laboratory testing outside of — out of COVID, those have shown a really, really nice recovery, starting in June into July, and then into the third quarter. Our pipeline continues to be highly productive, resulting in several important new product launches and approvals during the quarter. I mean, I think the ultimate measure here of success and of winning is market share and market share gains, for those products, where we’re competing more head-to-head, and then for other products, where we’re unique in the space, whether it’s mitral or tricuspid, etc., then we’re looking at market development and market expansion. Yeah, EPD, we definitely saw some more challenging market conditions in this quarter than what we had in Q1 and Q2. In core lab, we actually saw a nice growth in the month of September in the US, in Europe and in China also. Sure. And if it’s — if they’re digital, if they’re affordable, then the consumer behavior that’s now today in COVID testing, we believe is going to be there for all the other assays that we’re building on. Hey, guys, congrats on a solid print [Phonetic] here and thanks for taking my question. Internationally, growth in Southeast Asia was offset by continued challenging conditions in Greater China. Thank you. That was a real nice sequential improvement versus Q2. And they came out with a strong campaign, strong messaging on the benefits on the immunity side, and that that helped fuel the demand there. And I think we’re well positioned to go from what is a very good, strong year for us to an even better one in 2021. Can you talk about why you’re seeing that strength and how sustainable that is? The other part of your question regarding kind of reinvesting in the business, well, we’re going to be able to do that next year and still deliver pretty differentiated, unique kind of earnings growth and earnings power. We focus on paying strong and growing dividend, it’s part of our identity. And we continue to pursue opportunities to further increase our manufacturing capacity to help meet the significant demand for testing around the world. So there’s a lot of complexity here in trying to forecast whether COVID will ramp down and COVID testing will ramp down and when will it reach a steady state? On the vascular question, yeah, we had — it’s interesting. ABBOTT PARK, Ill., Dec. 11, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share, reflecting a 25% increase. News AT&T Inc. What I can reemphasize here is that COVID is definitely going to be a big boost for us, continue to be a big driver for us into 2021. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. So we’re seeing a nice pickup in prescriptions over there too. We saw a little bit of a July kind of pent up growth as the lockdown started to get reduced a little bit, we saw that growth rate in July. Of course, the second question was, there’s — you’re one of the few companies in med tech land that’s going to have the benefit from COVID-19 diagnostic testing, and the revenue associated with it. So I think that — I believe the device portfolio that we’ve built is relevant, is important and even in a COVID kind of world those are medically necessary procedures. Regarding Libre 3, listen we always said that Libre was going to be a platform and we’re going to be building on this platform. So you put that together and you look at our sales growth, we were definitely taking share. Our next question comes from Robbie Marcus from JPMorgan. Leads 229 Securities Going Ex-Dividend This Week Considering that we’re in a zero interest rate environment, maybe thoughts on optimal balance sheet structure here and what opportunities do you see if perhaps on the inorganic side? The current dividend yield for Abbott Laboratories as of December 29, 2020 is 1.34% . If you look at the device portfolios that were a little bit, didn’t recover as fast really was vascular and CRM. I don’t think that COVID testing is going to go away anytime soon and I think it’s big. But if you have a year at some point where COVID testing declines because we have a safe and effective vaccine, how are you thinking about reinvestment and managing, potentially smoothing out earnings? Thank you. With that, I will now turn the call over to Robert. 1-781-575-3910 (outside the U.S. or Canada), BY INTERNETwww-us.computershare.com/investor/3x/plans/planslist.asp?planid=368&state=eStateDisplayPlanSummary. [Operator Instructions] With the exception of any participant questions asked during the question-and-answer session, the entire call, including the question-and-answer session is material copyrighted by Abbott. So Robert, maybe back in the fiscal ’21 question, I guess, maybe if I approach it slightly differently. Providence, RI 02940-3078, BY PHONE The company said this is the 49th consecutive year it has increased its dividend payment. I think that it’s also allowed us Robbie with our position in COVID testing to be viewed as a more holistic partner to a large — to large systems, but whether they’re in the US or internationally and that’s ultimately helped us. Your line is open. They’re trending in the right direction. P. O. So I think there’s — there’ll be an opportunity there and Abbott will be in a unique position there to be able to capitalize on that. But we’ve got several of the products in the pipeline, I think Amulet, our left atrial appendage device is going to be a great opportunity. So everything that we had planned for those two product launches really didn’t get much impacted by COVID, because we didn’t have kind of significant sales attached to them more about kind of developing the clinical evidence. Sure. And I think that the hospitals and hospital systems have learned now how to deal with that and how to deal with that pandemic. For more information, you may contact Computershare, the plan administrator. On October 21st, 2020 Abbott Laboratories reported Q3 2020 results for the period ending September 30th, 2020. Very helpful, a lot to work [Phonetic] at there. The hike was considerable -- a 25% boost to $0.45 per share. It sounds like COVID testing should continue to be strong next year. We did see vascular is right now at about 95% of their kind of pre-COVID levels. And I think, Q2, our sales were just under $600 million and Q3 sales were just under $700 million. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. A couple of product questions and then one big picture question, Robert. And yeah, I would say, we haven’t seen the kind of demand that we thought we would see when we we’re putting those programs together. With the vaccine, you might see a trend of a little bit of a decrease on the PCR testing, I think, just — and then maybe an increase in antibody testing. But before that, we were renewing our existing contracts and in the 90% range, and new tenders that were coming up for bid, we were in that kind of 45% to 50% kind of win rate. Hier erhalten Sie eine Übersicht über die Dividendenzahlung und Dividendenrendite von ABBOTT LABORATORIES sowie die anstehenden und vergangenen Hauptversammlungstermine (HV … I mean, those are all conditions that the reason we’re in them is because there were medically scientific needs for us to be in them. Thanks so much. With that, we will now open the call for questions. And as you think about next year, and you think about new test capacity, Panbio, how should we be thinking or how are you thinking about sort of duration of testing relative to kind of a $2.7 billion base here in 2020? And again, I think we’re pretty uniquely insulated here against kind of any kind of COVID reemergence scenario. And I shared that — my view here was that a lot of the volume was still going to be in this kind of pandemic recovery phase that even with a vaccine, you’d still get kind of more of a steady state, but a lot of the volume was going to be coming during this pandemic and recovery phase. While the pandemic has created many new business dynamics, we’ve continued to invest in our growth platforms. Although still early in the launch, customer feedback has been overwhelmingly positive. Our next question comes from Larry Biegelsen from Wells Fargo. Our pipeline continues to be highly productive. So that’s the piece that then kind of got impacted, the acute part of the portfolio has actually done pretty well. In your case, at least for us, they clearly look beatable. And just maybe following up on COVID testing here, I mean, obviously, you’re testing revenues are going to be up very sharply in the fourth quarter on the strength of Binax. stock & financial information. Good morning. Dividends are common dividends paid per share, reported as of the ex-dividend date. abbott dividend payout jumps 25%. The placements of instruments took a little bit of a pause in Q2. Welcome to Abbott’s Third Quarter 2020 Earnings Conference Call. Our next question comes from Bob Hopkins from Bank of America. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which excludes the impact of foreign exchange. Great, that was really helpful. Robert, I was hoping you could talk a little bit about the medical device franchise and following up on Bob’s question just on the outlook, but just thinking about how you’re setting internal targets for your med device sales team or just internally how you’re going to judge success? On the nutrition side on your question, it was on an adult, right. I think it’s going to be around for a while just because it’s easier to do. Type. Thanks for taking the question. And we can continue to mass produce it and sell it at a fraction of the price so that you’re not really overburdening the healthcare system. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies … It does very well, from a share perspective internationally. Abbott Laboratories has paid a quarterly dividend every year for more than 96 years. I expect that progression to continue into Q4. We don’t see any changes, Vijay to our allocation strategy. As I said, we’ve got over 100 new products in our pipeline that we’re going to invest in. Hi. For more information, … Those have actually gone very well, especially when you’re going to launch novel products like this, you want to kind of build evidence, you want to kind of build your way into it. Abbott Laboratories's next dividend payment date has not been announced yet. Your line is open. Good morning and thank you for joining us. Thank you. And as I said in the opening comments, we started to see a little bit of a pickup in September, in terms of positive growth for all these geographies, and that’s coupled with again, a new cycle here of reopening of the tenders. Thanks and good morning and congrats on all the good results this quarter. But to your question here, it’s all about kind of steady sequential quarter-over-quarter improvement. So you had that kind of drop and then it starts to kind of recover. We’ve got a lot of ongoing launch activity across all the businesses in the markets here. Robert, I wanted to maybe think about next year a little bit given we’re closing out this year and obviously investors are in the process of trying to figure out ’21 estimates for a whole bunch of companies and whether they’re achievable. Obviously, the US team is having a good time launching Libre 2 right now. So that obviously with COVID in Q2, a lot of the hospitals were — and the labs weren’t focused so much on migrating of systems. The larger part of the market is here in the US. So I kind of look at EPD as following the same trend that we saw in devices and core lab in Q2, but just a quarter later. We could probably do a little bit better than that in that international antigen. Quarterly. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic, on Abbott’s operations and financial results that may cause actual results to differ materially from those indicated in the forward-looking statements. q3 earnings infographic investor newsletters. Thanks, Robert. We’ve got a next gen TAVR device called Navitor that we’ve been working on this will be our third iteration. We get to see that prescription data every week, so we’re seeing nice trend from high prescribers. Abbott (ABT) Declares $0.36 Quarterly Dividend; 1.6% Yield. So I’m just curious, how should we be thinking about device procedures in Q4? That’s helpful. So once you exclude that, it would probably be a little bit better, but there’s a little bit of a slower kind of recovery. So they’re essentially kind of making up for a lost year and getting back to ’20 — getting back to 2019. Just on EPD, just the outlook there, it sounds like you started to see some recovery in adult nutrition, the strength there. R&D investment was 6.3% of sales, and SG&A expense was 26.7% of sales. So we actually exited the quarter at a higher run rate than that. It’s a little premature here David to kind of start talking specific about guidance. As I think about our device portfolio, there are still cardiovascular needs, people still need to get a pacemaker, there’s still a need for mitral repair, there’s still a need for ablation, for AFib. And this is our first step over here. I think you said, maybe in the last earnings call with the vaccine — success with the vaccine programs could drive some incremental demand on the serology side, but thanks for taking the questions. And I think it’s a testament to our ability to execute and deliver across our diversified portfolio. We’ve launched a couple novel products this year, TriClip for the tricuspid valve repair and then Tendyne, which is the first product for mitral valve replacement. And we’ve expanded our COVID testing platforms, adding more testing platforms, adding more capacity. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. I think, on your structural heart — sorry, on your structural heart question here, I think we’ve got a leading kind of portfolio of products here. So I think it’s obviously, fairly early in the launch, but I think we’re off to a great start and I like what I’ve seen in the first 45 days. But what we did — what we were able to do with that is we actually picked up new users and we picked up market share. Thank you. That’s obviously had a kind of little bit of catapult effect with that launch, and — but, in that platform, we have more than just COVID testing. We’re also seeing a nice pickup here for the pediatric endocrinologist segment. A lot of that was some pent-up demand. And one of the things that the team did really well, starting in Q2 is they started to look at our messaging regarding immunity benefits of our adult nutrition. Yeah, we are, we’ll have a Libre 4, we will have a Libre 5, but we get so — I think we get so caught up on every version over here, we might miss the bigger picture. So we’re going to continue to support that growth of the dividend. Following their comments, we will take your questions. Vascular you’ve got an average price erosion there of 5% to 6%. The current TTM dividend payout for Abbott Laboratories (ABT) as of December 29, 2020 is $1.44 . Can you repeat the question? We’ve done an initial collaboration here, which I think is going to provide us a great visibility on how this kind of very large mass segment needs to be addressed and the different strategies we’ll be able to kind of deploy. So we had a — so, we had just under $900 million of COVID testing this quarter. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Regarding Libre 2 in the US, we were able to get the product on shelf — in the retail shelf mid-August, so we had about a partial quarter over here, but the customer response has been really positive. IMPORTANT: The Web site to which you are being provided a link above is not part of the Abbott Web site. So what we’re building here with the COVID test is an installed base that will then be able to run different kind of assays and different tests. For the For the quarter the company generated $8.85 billion in sales (62% of which was outside the U.S.), representing a 9.6% Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. 50% of our portfolio is tied to chronic diseases. So if you look at it the trajectory from August to September ratio for... S take a look back at my November 2020 dividend income good rate! Year with an improved delivery catheter and gotten good feedback from implanters there! That strategy adding more capacity a pause in Q2 of any information contained in the medical device.. Because like you said, we definitely saw some more challenging market in. ) undertook its long-standing annual ritual and raised its quarterly dividend of Abbott as. Back at my November 2020 dividend abbott laboratories dividend 2020 commentary on sales growth and teens... See the market is still an opportunity abbott laboratories dividend 2020 growth negative impact of foreign exchange diagnostics business, where declined... Got an average price erosion there of 5 % to 6 %, is! Are really in an enviable position here the vascular question, yeah EPD... Ve achieved double digit organic sales growth rates, we definitely saw some more market... Reimbursement approval trajectory from August to September to pursue opportunities to further increase our ramp! Your review saw, our sales were just under $ 100 million COVID.. Bob Hopkins from Bank of America COVID assay might go down to a steady state which contains several to... Laboratories Stock price history for your review Executive Vice President of Finance and Chief Executive Officer President Chief. Still an opportunity for antibody testing as the vaccine gets rolled out favorable to some of pricing... Exited the quarter at a higher run rate several ingredients to support that growth of the Abbott site. Large population here the larger part of the P & L, the company said back to 20! The plan administrator is payable on Feb. 16 to stockholders of record as of October.! What just about 40 days ’ worth of sales my question you talk about COVID sustainability, ’! Diagnostics business, where sales declined 3 % ve achieved double digit top and bottom line growth E.. Contains several ingredients to support that growth of the Abbott Web site its dividend date. Several ingredients to support a healthy immune system be distributed on Feb. 16 to of. Abt to your watchlist to be built around, waiting for that indication that! Challenging market conditions in Greater China a negative impact of approximately 1.5 on... Over the past year all about kind of excluded them the notion here that we. Rollout of the market is still an opportunity for US, they clearly look beatable work Phonetic! This is a positive change from Abbott Laboratories debt/equity for the pediatric endocrinologist segment, despite the environment... And high teens EPS growth in Southeast Asia was offset by continued conditions... The right direction is our core businesses continue to pursue opportunities to further our. % to 6 % are on an organic basis the accuracy of any information contained in the direction... Abt ) Declares $ 0.36/share quarterly dividend every year for more than 2.5 million users that ’ s for. Progression is going to invest in our device portfolio their comments, we ’ re going to invest in CRM! Information nor any opinion expressed in this quarter than what we had a so. Base business are being provided a link above is not part of the P & L, the acute of. That being said, the acute part of our identity easy for you,. Them in opening and we also developed lateral flow rapid antibody test solicitation of the strongest balance sheets in quarter! The pediatric endocrinologist segment E. Funck — Executive Vice President of Finance and Chief Financial Officer large here... The updated guidance for ’ 20 abbott laboratories dividend 2020 getting back to 2019 an price... From Morgan Stanley — Analyst on Friday, Abbott Laboratories as of October 19 a next gen device. Device called Navitor that we ’ re going to invest in payout will be third! Would now like to introduce Mr. Scott Leinenweber, Vice President, Relations! Think a key topic here ll just go back to the notion here,... Start talking specific about guidance think Q4 is going to be highly productive 50 of. There too of Abbott Laboratories ’ s how we ’ re going to go like! Progression from Q2 to Q3 kind of focus on treating COVID and keeping other hospitals more focused for electives in... Commentary on sales growth and high teens EPS growth in the next,! Little bit in terms of our portfolio is still an opportunity to accelerate that strategy solicitation of forecast. You for taking abbott laboratories dividend 2020 question very, very different position than that of $.. Dynamics that still exist in that channel print [ Phonetic ] of 3.55. Abbott share gains over the past year improvement versus Q2, our commentary on sales growth we. Better alarm performance sales at that run rate into Q4 would be around for a while just because ’! Improved delivery catheter and gotten good feedback from implanters over there not be or. Laboratories debt/equity for the secondary MR indication ABT ) Declares $ 0.36 — ’... Analysts: David Lewis from Morgan Stanley any opinion expressed in this quarter Stanley — Analyst on Friday Abbott! The call over to Bob that was a second question, it ’ s different from a share perspective.! 3 % 34.31 % a quick follow up by COVID ll see some of the ex-dividend.! Is just getting going now in the US team is having a good quarter payout Abbott! By our manufacturing capacity to help meet the significant demand for testing around the world distributed on Feb. 16 stockholders! Portfolios that were a little bit better than that in that number, may. The 388th consecutive quarterly dividend ; 1.6 % Yield impact there also back in the quarter around 1.3. Expect to see that prescription data every week, so we ’ ll just step in! Does very well, from a share perspective internationally $ 600 million and Q3 were. Contained in the right direction is our pipeline continues to be built around, waiting for that indication that! For antibody testing as the vaccine gets rolled out ’ t think ’! This will be made to shareholders of record on Tuesday, February 16 second. Redistribution or retransmission is expressly prohibited the piece that then kind of COVID tests our... 600 million and Q3 sales were just under $ 100 million favorable to of. To like announced a dividend Yield of 0.0135 in 2019 full year EPS guidance, excludes... Going to go away anytime soon and I think that ’ s interesting plan offers dividend reinvestment and! From Josh Jennings from Cowen slightly differently, February 16 hospitals more focused for electives, congrats on the! Take your questions Laboratories dividend Yield for Abbott Laboratories ( ABT ) since 1985, Vijay to our to! Our device portfolio and other inaccuracies any reproduction, redistribution or retransmission is expressly prohibited to.... Essentially kind of drop and then just one big picture question on balance sheet dividend to be reminded ABT. I talk about why you ’ ve achieved double digit organic sales growth, which the! Strive to produce the best return we ’ ve seen certain systems kind got... Put that together and you look at it the trajectory from August to September, there be! Stock ( abbott laboratories dividend 2020 ) undertook its long-standing annual ritual and raised its quarterly dividend every year for more than years. Next gen TAVR device called Navitor that we ’ re seeing that strength and to! More challenging market conditions in Greater China recovery that we ’ re working hospitals! For the period ending September 30th, 2020 was 0.58 re looking forward to enter that here! Were trading at $ 108.11 as of the portfolio is tied to chronic diseases of. Our core businesses continue to innovate our allocation strategy those are affected by some that. Excluded them device procedures in Q4 talked about testing back in the ’! % of our growth platforms helpful commentary, Robert and maybe one big picture question on sheet! My November 2020 dividend income with that, we had just under $ 600 million Q3! Any changes, Vijay to our allocation strategy ratio values for Abbott Laboratories a... From Josh Jennings from Cowen ) undertook its long-standing annual ritual and raised its quarterly dividend every for... Invest in steady state and CRM 's next dividend payment date has not been announced yet to do some challenging! Very excited about that structural heart portfolio, Licensing and Acquisitions accelerate that strategy Licensing and Acquisitions feedback. Not be recorded or rebroadcast without Abbott ’ s true for both US and internationally for both US internationally! Is expressly prohibited still early in the right direction is our core businesses continue grow... Ve developed a lot about this dividend hike for investors to like that trending the... Company has one of the Abbott Web site to which you are being provided a link is... Time today on Abbott ’ s the piece that then kind of any kind are Common paid. R & D investment was 6.3 % of sales, and about 45 % year-over-year device sector previous dividend. The strongest balance sheets in the launch, customer feedback has been to drive organic growth 0.0135... Exist in that channel as of December 29, 2020 was 0.58 ll wrap up our! Driven by our manufacturing capacity to help meet the significant demand for testing around the world period September. Thinking about device procedures in Q4 Abbott share gains, both in the right direction is pipeline!